Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: February 24, 2009
Last updated: October 30, 2015
Last verified: October 2015